

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116

Serial Number: 09/150,813

Filing Date: September 11, 1998

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Page 2

D.t.: 1543.002US1

preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14), wherein the dosage form is linked to a site targeting moiety.

66. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of a peptide Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

67. (New) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

68. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

69. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74, wherein the dosage form is linked to a site targeting moiety.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.116

Serial Number: 09/150,813

Filing Date: September 11, 1998

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Page 3

D.L.: 1543.002US1

70. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

71. (New) A method of preventing or inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

72. (New) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

73. (New) A method to modulate the chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

74. (New) A method to enhance or increase hematopoietic cell-associated activity at a tumor site, comprising: administering an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

Remarks

Claims 17, 20, 22, 34, 41-44 and 52-62 are canceled, and claims 63-74 are added; as a result, claims 63-74 are pending.

At page 7 of the final Office Action dated August 10, 2001, the Examiner indicated that claims 57-58 and 60 were objected to as being dependent upon a rejected base claim, but would